EyeKor Adds Stephen Travers to Team of Ophthalmic Clinical Trial Experts
Madison, WI (PRWEB) September 06, 2016 -- EyeKor, Inc., a Software-as-a-Service (SaaS) company offering a complete spectrum of integrated ophthalmic clinical trial image data management and analysis services, has hired Stephen Travers as its new Senior Director of Clinical Research.
Travers brings many years of experience in ophthalmic imaging and clinical trials to EyeKor. He has held previous positions as Director of Ophthalmic Imaging at Baylor College of Medicine in Houston, TX; Principal Clinical Research Scientist at Alcon in Fort Worth, TX; and Manager of Clinical Affairs at Heidelberg Engineering in Germany. With a special interest in retinal disease imaging and its application in clinical trials, Mr. Travers has played a major part in the recognition and approval of autofluorescence imaging as an endpoint in clinical studies for age-related macular degeneration.
“I am very excited to be joining this young and dynamic company,” Travers says. “My vision and goals are to see the integration of EyeKor’s technology platforms into all ophthalmic pharmaceutical clinical trials, and to foster a closer collaboration with pharmaceutical sponsors, selected ophthalmic reading centers, and clinical imaging sites. I believe my career experience will be of considerable benefit to Eyekor.”
EyeKor’s hiring of Travers comes at an opportune time. In the last three years, EyeKor has experienced exponential growth. EXCELSIOR™, EyeKor’s cloud-based software application for supporting image data collection and management of ophthalmic clinical trials, is used in more than 40 ophthalmic clinical trials sponsored by both federal agency and industry partners. Currently, the EXCELSIOR™ platform is being used at more than 750 ophthalmic clinical sites from 38 countries by more than 4,000 certified ophthalmic imaging technicians and site coordinators. To date, the Excelsior platform has hosted more than 4 million ophthalmic images.
“Imaging continues to be a critically important element in ophthalmic clinical trials. As we have seen in many clinical trials, imaging-based in vivo biomarkers help guide our understanding of disease progression and treatment effects. EyeKor is well positioned to offer the kind of imaging expertise that ophthalmic clinical trial sponsors need,” says EyeKor CEO, Christopher J. Murphy, DVM, PhD, DACVO.
To learn more about EyeKor and EXCELSIOR™, go to http://www.eyekor.com/ or contact Chief Technology Officer Yijun Huang, PhD, at (608) 886-3386 or yhuang(at)eyekor(dot)com.
About EyeKor: EyeKor, Inc. is a Software-as-a-Service (SaaS) company that offers a complete spectrum of integrated ophthalmic clinical trial image data management and analysis services, from preclinical to clinical phases I-IV. EyeKor expertise encompasses a diverse array of ophthalmic testing methods including fundus photography and angiography, optical coherence tomography, fundus autofluorescence imaging, automated visual field testing, and electrophysiological testing. EyeKor’s cloud-based software application, EXCELSIOR™, was built specifically for supporting image data collection and management of ophthalmic clinical trials. EXCELSIOR™ utilizes the latest web and imaging technologies for data standardization, analysis, grading and reporting. EXCELSIOR™ is cleared with FDA as a class II medical device, with specific indication for use for managing ophthalmic clinical trials.
Media Inquiries:
Yijun Huang, PhD
Chief Technology Officer
(608) 886-3386
yhuang(at)eyekor(dot)com
Luca Sergio, Ethis Communications, Inc., http://www.ethiscommunications.com, +1 (212) 791-1440, [email protected]
Share this article